The Patient-Derived Xenograft and Preclinical Therapeutics (PDX-PCT) Core at OMRF provides high quality services for basic and translational cancer research, drug discovery and personalized cancer therapy. The main focus of the PDX-PCT Core is to generate the most current and sophisticated patient-derived in vivo cancer models to improve preclinical evaluation of drugs efficacy towards more personalized medicine.
Patient-derived xenograft (PDX) models are believed to be one of the most clinically relevant tumor models, which faithfully recapitulate the original patient tumor histology, genetic profile, and response/resistance to therapy. Under IRB and IACUC approvals, we derive PDX models directly from tumor tissue of patients undergoing therapy at Stephenson Cancer Center. We expand PDX tumor models in vivo for 3-4 passages, characterize established PDX models based on tumor type, histology and molecular profile, maintain a collection of PDX lines cryopreserved in our Biobank and distribute PDX models (passages 3 and up) to OMRF or OU Researchers. The preclinical tumor models generated at OMRF are utilized to understand the development, progression and metastasis of human cancer with the ultimate goal to develop and validate the best treatment strategies for patients suffering from this devastating disease.
In addition to development of PDX models, we provide the expertise and resources necessary to perform a wide variety of in vivo studies related to tumor biology and preclinical testing of new therapies. Our area of expertise include:
- establishment of patient-derived or cell line based xenografts
- advanced tumor monitoring and imaging
- preclinical drug efficacy studies
- preclinical toxicology studies
- tissue collection, preservation and banking
- in vivo data management and analysis